GlassScriptPhysician profile
Garrett J Nelson
NPI 1295098440
$5,610.48
in general payments reported to CMS, 2019-2025
33 companies · $703 in 2025
The $703 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,697 · 2020: $388 · 2021: $551 · 2022: $920 · 2023: $748 · 2024: $604 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,054.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,076.95 | 2019-2025 | |
| Lilly USA, LLC | $686.07 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Novartis Pharmaceuticals Corporation | $624.82 | 2019-2025 | |
| Janssen Biotech, INC. | $452.85 | 2019-2025 | Tremfya, Tecvayli |
| Sun Pharmaceutical Industries INC. | $378.68 | 2019-2025 | Ilumya |
| Amgen INC. | $324.50 | 2020-2025 | Otezla, Otezla |
| Allergan, INC. | $307.82 | 2019-2022 | |
| Celgene Corporation | $242.06 | 2019 | |
| Genzyme Corporation | $150.60 | 2019-2025 | |
| Ucb, INC. | $145.61 | 2019-2025 | Bimzelx |
| Leo Pharma INC. | $134.92 | 2023-2025 | Adbry |
| Regeneron Healthcare Solutions, INC. | $118.20 | 2019-2024 | Libtayo |
| Pfizer INC. | $101.30 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $78.82 | 2023-2024 | Sotyktu |
| Stryker Corporation | $75.73 | 2025 | Iconix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Prugen, INC. Pharmaceuticals | $72.37 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $68.89 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $67.42 | 2022-2024 | Spevigo |
| Kerecis Limited | $66.95 | 2022-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Galderma Laboratories, L.P. | $63.69 | 2019 | |
| Dusa Pharmaceuticals, INC. | $60.17 | 2019 | |
| Incyte Corporation | $52.81 | 2024-2025 | Opzelura |
| Vyne Pharmaceuticals INC. | $50.51 | 2020 | |
| Genentech USA, INC. | $37.18 | 2019-2022 | |
| Aclaris Therapeutics, INC. | $32.61 | 2019 | |
| Krystal Biotech INC | $24.08 | 2023 | Vyjuvek |
| Janssen Scientific Affairs, LLC | $21.03 | 2020 | |
| Biofrontera INC. | $20.47 | 2019 | |
| Arcutis Biotherapeutics, INC. | $17.23 | 2023 | |
| Fresenius Kabi USA, LLC | $15.46 | 2024 | Idacio |
| Organon LLC | $15.09 | 2024 | |
| Paratek Pharmaceuticals, INC. | $13.87 | 2022 | |
| Dermira, INC. | $11.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.